CStone Pharmaceuticals
Zhen-Fang Zhou is a highly experienced professional with extensive expertise in medical writing and research. Currently serving as the Manager of Medical Writing at 基石药业 since June 2019, Zhen-Fang has held previous positions including a Postdoctoral Researcher at Rice University, focusing on the biosynthesis of secondary metabolites, and a Research Assistant at MD Anderson, studying metabolic pathways in Neuroendocrine Prostate Cancer. Zhen-Fang's skills encompass laboratory management, experimental design, and data analysis, complemented by a strong background in medical consulting for leading pharmaceutical companies such as Wyeth and Roche. Zhen-Fang holds a PhD in Medicinal Chemistry from the University of Chinese Academy of Sciences and a Bachelor's degree in Traditional Chinese Medicine from China Pharmaceutical University.
CStone Pharmaceuticals
CStone is a biopharmaceutical company focused on developing and commercializing innovative immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and worldwide. Established at the end of 2015, CStone has assembled a world-class management team with extensive experience in innovative drug development, clinical research, and commercialization. With a strategic emphasis on immuno-oncology combination therapies, the Company has built an oncology-focused pipeline of 16 drug candidates, including 5 late-stage candidates at pivotal trials or registration stages. With an experienced team, a rich pipeline, a robust clinical development-driven business model and substantial funding, CStone’s vision is to become a world-renowned biopharmaceutical company that is leading the way to conquering cancer.